Alzheimer's

“I think this is going to be the disease, and maybe one of the biggest health care political issues of my generation,” says Robert Essner, 59, Wyeth’s professorial chief executive. “It’s hard for anyone to envision how to provide health care in the United States if you’re going to have to deal with the burden. You just start to add up the cost, 20 years from now as my generation gets old — it’s phenomenal.”

This is from "Taking On Alzheimer’s" in the NY Times on how lots of money is being spent by drug companies to develop medicines to blunt the progress or even cure the disease, which because of the aging population will become a larger problem in the near-future.